

Table S1: Patient level information for all patients with PLA2R related disease and follow up data (N=33)

PID	Therapy	Baseline anti-PLA2R (u/ml)	PLA2R end of therapy	Protein/creat baseline (g/g)	Protein/creat end of therapy (g/g)	Remission end of therapy	Follow up time (months)	Final outcome
1	MMF	141	negative	9.11	0.28	y	60	Remission
2	MMF	144	positive	7.86	6.19	N	60	Persistent proteinuria
3	MMF	234	negative	9.91	1.01	Y	60	Remission
4	MMF	16260	positive	15.13	2.46	Y	10	Relapse
5	MMF	62	negative	11.32	9.20	N	24	Immunosuppr. therapy
6	MMF	424	positive	25.20	6.68	N	5	Immunosuppr. therapy
7	MMF	2917	positive	24.44	9.46	N	0	Relapse
8	MMF	431	negative	19.67	6.60	N	55	Relapse
9	MMF	129	negative	12.29	1.44	Y	60	Remission
10	MMF	163	negative	13.65	0.19	Y	44	Relapse
11	MMF	906	positive	10.47	5.46	N	20	Dead
12	MMF	253	negative	12.40	0.27	Y	60	Remission
13	MMF	190	positive	12.73	2.37	Y	22	Dead
14	MMF	3000	negative	12.34	1.99	Y	60	Remission
15	MMF	3730	positive	6.48	0.35	Y	3	Relapse
16	CF	590	negative	7.79	1.13	Y	60	Remission
17	CF	203	negative	4.37	0.19	Y	60	Remission
18	CF	455	negative	11.91	0.89	Y	60	Remission
19	CF	333	positive	10.38	5.22	N	5	Immunosuppr. therapy
20	CF	1241	negative	3.18	1.41	Y	60	Remission
21	CF	200	negative	7.05	0.88	Y	60	Remission
22	CF	229	negative	8.84	0.48	Y	60	Remission
23	CF	267	negative	13.29	2.94	Y	23	Relapse
24	CF	167	negative	4.69	0.19	Y	21	Relapse
25	CF	264	negative	7.75	0.60	Y	40	Relapse
26	CF	41	negative	3.35	1.79	Y	49	Relapse
27	CF	1385	negative	10.49	0.21	Y	60	Remission
28	CF	480	positive	12.82	8.36	N	0	Relapse
29	CF	1250	negative	10.88	0.16	Y	34	Relapse
30	CF	2150	negative	10.29	0.98	Y	14	Dead
31	CF	1430	negative	8.84	0.75	Y	60	Remission
32	CF	1350	negative	13.05	1.15	Y	13	Relapse
33	CF	1580	negative	15.22	2.67	y	60	Remission

Table S2: Outcome per tertile of baseline PLA2R-ab titer in PLA2R related disease (N=33)

	Initial response: remission	Remission*	Relapse*	Persisting proteinuria*	Immunosuppr. therapy	Dead
40-230 (N=11)	9	5	3	1	1	1
232-1129 (N=11)	6	4	4	0	2	1
≥1130 (N=11)	10	5	5	0	0	1

*Outcome ascertained at final follow-up (5 years).

No significant differences observed.

Table S3: outcome in patients with PLA2R-related disease who were PLA2R-ab negative at end of therapy

	mycophenolate mofetil (N=8)	cyclophosphamide (N=16)
Persistent remission	5	9
Relapse / persistent proteinuria/immunosuppr. therapy	3	6
Dead	0	1

No significant difference observed.